Activation of human T cells obtained pre-and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment
G Weil-Hillman, K Schell, DM Segal… - Journal of …, 1991 - journals.lww.com
The role of activated T cells in the mediation of antitumor responses has been documented
in several experimental models. In some of these, interleukin-2 (IL-2) has been used as a …
in several experimental models. In some of these, interleukin-2 (IL-2) has been used as a …
Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
JA Hank, M Albertini, OH Wesly, JH Schiller… - Clinical cancer research …, 1995 - AACR
Anti-CD3 mAb and interleukin 2 (IL-2) were used in a Phase I study to treat 29 patients with
cancer. The anti-CD3 was given as an iv bolus infusion over 10 min followed by two iv 96-h …
cancer. The anti-CD3 was given as an iv bolus infusion over 10 min followed by two iv 96-h …
A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patients
JA Sosman, C Kefer, RI Fisher, CD Jacobs… - Journal of …, 1995 - journals.lww.com
Preclinical studies have shown that anti-CD3 antibodies can enhance the in vitro activation
of human T lymphocytes in combination with low-dose interleukin-2 (IL-2) and induce the in …
of human T lymphocytes in combination with low-dose interleukin-2 (IL-2) and induce the in …
Anti-CD3 enhancement of cellular cytotoxicity in cancer patients treated with interleukin-2.
SS Ubhi, T Horsburgh, PS Veitch, PR Bell - Anticancer research, 1991 - europepmc.org
Anti-CD3 monoclonal antibody was found to enhance non-MHC restricted cellular
cytotoxicity in vitro in the peripheral blood mononuclear cells from normal healthy …
cytotoxicity in vitro in the peripheral blood mononuclear cells from normal healthy …
Potential for specific cancer therapy with immune T lymphocytes
MA Cheever, PD Greenberg, A Fefer - Journal of Immunotherapy, 1984 - journals.lww.com
In animal models, advanced disseminated tumors can be specifically eradicated by
infusions of T lymphocytes immune to tumor. The most successful regimens require a …
infusions of T lymphocytes immune to tumor. The most successful regimens require a …
Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and-dependent components.
W Stohl, Z Tovar, N Talal - Journal of immunology (Baltimore, Md …, 1990 - journals.aai.org
We have generated potent Ag-nonspecific cytolytic activity in PBMC cultures without
exogenous IL-2 by stimulating the cells with anti-CD3 mAb. Three anti-CD3 mAb (147, 446 …
exogenous IL-2 by stimulating the cells with anti-CD3 mAb. Three anti-CD3 mAb (147, 446 …
In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti‐tumor cytotoxic T lymphocytes
DH Lynch, AE Namen, RE Miller - European journal of …, 1991 - Wiley Online Library
The draining lymph nodes of mice injected with viable syngeneic tumor cells contain
lymphoid cells capable of generating anti‐tumor cytotoxic T lymphocytes (CTL) during a 4 …
lymphoid cells capable of generating anti‐tumor cytotoxic T lymphocytes (CTL) during a 4 …
Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor …
F Nakajima, A Khanna, G Xu… - Proceedings of the …, 1994 - National Acad Sciences
Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-
activated killer cells, has brought new hope to patients with cancer. The broad application of …
activated killer cells, has brought new hope to patients with cancer. The broad application of …
Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2
AL Rakhmilevich, RJ North - Cancer Immunology, Immunotherapy, 1994 - Springer
Experiments were undertaken to determine whether the depletion of CD4+ T cells from mice
bearing an advanced immunogenic SA-1 sarcoma would result in an enhanced ability of …
bearing an advanced immunogenic SA-1 sarcoma would result in an enhanced ability of …
T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in …
KD Crossland, VK Lee, W Chen, SR Riddell… - … (Baltimore, Md.: 1950 …, 1991 - journals.aai.org
The therapeutic efficacy of adoptive immunotherapy of cancer has been shown to positively
correlate with the dose of tumor-immune T cells transferred. Therefore, the success of this …
correlate with the dose of tumor-immune T cells transferred. Therefore, the success of this …